SCHEMBL2999879

SCHEMBL2999879

COc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3cccc(Br)c3)CC2)n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PSMD14 O00487 1/20 0.37
DRD2 P14416 5/20 0.36
DRD4 P21917 5/20 0.36
DRD3 P35462 5/20 0.36
MAPT P10636 5/20 0.34
HSD17B10 Q99714 2/20 0.34
HTT P42858 1/20 0.34
GHSR Q92847 2/20 0.34
HTR1B P28222 1/20 0.34
USP2 O75604 1/20 0.34
RECQL P46063 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
POLB P06746 1/20 0.34
GPR6 P46095 1/20 0.33
FKBP1A P62942 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3R1 P27986 1/20 0.33
PIK3CA P42336 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016957 0.91 TP53 (0.37) DRD2DRD4DRD3MAPTHSD17B10
SCHEMBL3018532 0.91 MAPT (0.36) MAPTHSD17B10HTTUSP2RECQL
SCHEMBL3013002 0.90 SMN1; SMN2 (0.38) DRD2DRD4DRD3MAPTHSD17B10
SCHEMBL3007560 0.90 KDM1A (0.40) PSMD14MAPTHSD17B10HTTMEN1
SCHEMBL3004393 0.90 MEN1 (0.41) DRD2MAPTHSD17B10USP2RECQL
SCHEMBL3017287 0.89 DNM1L (0.34) MEN1KMT2A
SCHEMBL3019256 0.89 TSHR (0.39) DRD2MAPTHSD17B10HTTUSP2
SCHEMBL3015530 0.88 DRD2 (0.40) DRD2DRD4DRD3MAPTMEN1
SCHEMBL3015867 0.87 ADORA2A (0.45) MAPTHTTKMT2A
SCHEMBL3016673 0.87 ALDH1A1 (0.36) DRD2DRD4DRD3GHSRHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA PSMD14 1950/4885DRD2 573/4885DRD4 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.